Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Olink Holding AB (publ) OLK
$21.67
+$0.08 (0.37%)
На 18:04, 12 мая 2023
+1.52%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
2848278600.00000000
-
week52high
26.47
-
week52low
8.39
-
Revenue
139848000
-
P/E TTM
-206
-
Beta
0.83429700
-
EPS
-0.11000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:00
Описание компании
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 12 авг 2022 г. |
| Goldman Sachs | Neutral | Neutral | 14 июл 2022 г. |
| SVB Leerink | Outperform | Outperform | 13 мая 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 13 мая 2022 г. |
| Goldman Sachs | Neutral | Neutral | 13 апр 2022 г. |
| SVB Leerink | Outperform | Outperform | 15 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 11 ноя 2022 г. |
| Scotiabank | Sector Outperform | 05 янв 2023 г. | |
| Canaccord Genuity | Buy | 14 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Olink: Proteomics Opportunity Exceeds Dilution Risk
Seeking Alpha
20 янв 2023 г. в 02:38
Olink is a Health Care Tools and Service company focusing on leveraging the new high-growth field of proteomics. Olink just announced a dilutive offering and the share price fell over 16% on the news.
Why Is Olink (OLK) Stock Down 17% Today?
InvestorPlace
19 янв 2023 г. в 09:29
Olink (NASDAQ: OLK ) stock is falling on Thursday as investors react to the pricing of a public offering of the proteomics company's shares. The offering prices 5,831,028 American Depository Shares ( ADS ) of OLK stock at $20 each.
Is Olink Holding (OLK) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
29 ноя 2022 г. в 11:17
Here is how Olink Holding AB publ Sponsored ADR (OLK) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.
5 Best Stocks to Invest in for Solid Earnings Acceleration
Zacks Investment Research
17 ноя 2022 г. в 08:17
Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & LivePerson (LPSN) at the moment for superb earnings acceleration.
Olink Holding AB (publ) (OLK) Q3 2022 Earnings Call Transcript
Seeking Alpha
11 ноя 2022 г. в 19:30
Olink Holding AB (publ) (NASDAQ:OLK ) Q3 2022 Earnings Call Transcript November 10, 2022 8:00 AM ET Company Participants Jan Medina - Vice President, Investor Relations & Capital Markets Jon Heimer - Chief Executive Officer Carl Raimond - Chief Commercial Officer Oskar Hjelm - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Olink Proteomics Third Quarter 2022 Earnings Conference Call.